We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




First Direct Measurement of Dementia-Linked Proteins to Enable Early Alzheimer’s Detection

By LabMedica International staff writers
Posted on 10 Nov 2025

The disease process in Alzheimer’s begins long before memory loss or cognitive decline becomes apparent. More...

During this silent phase, misfolded proteins gradually form amyloid fibrils, which accumulate in the brain and cause irreversible damage. Current diagnostic techniques can rarely identify these early changes, meaning treatments often begin too late to be effective. Now, a breakthrough method could help detect the earliest stages of Alzheimer’s disease years before symptoms appear.

For the first time, researchers at Utrecht University (Utrecht, Netherlands) have made the growth of harmful protein clumps involved in dementias such as Alzheimer’s, Parkinson’s, and Huntington’s directly measurable — even in blood samples. The team, in collaboration with colleagues from international institutes, has developed FibrilPaint — a new class of molecules that “paint” the earliest fibril formations. FibrilPaint binds specifically to the thread-like amyloid protein aggregates characteristic of dementia and emits fluorescent light when exposed to specialized imaging equipment.

This fluorescence not only confirms the presence of the fibrils but also reveals their length and growth stage, offering a measurable indicator of disease progression. Importantly, FibrilPaint allows scientists to analyze blood and cerebrospinal fluid directly, eliminating the complex, time-consuming pretreatment steps required by existing methods.

The researchers believe FibrilPaint could revolutionize both early diagnosis and drug development for neurodegenerative diseases. By tracking disease progression in unprecedented detail, the technique, published in the journal PNAS, will allow clinicians to evaluate treatment effectiveness in real time.

“With our technique, we will soon be able to monitor the progression of the disease much more precisely and determine whether a treatment is effective,” said Françoise Dekker, a chemist at Utrecht University. “Our technique will eventually allow us to follow the course of the disease much more accurately and see whether a treatment really works.”

Related Links:
Utrecht University


New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Online QC Software
Acusera 24•7
Multi-Chamber Washer-Disinfector
WD 390
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.